From: Prevalence of chronic kidney disease in Saudi Arabia: an epidemiological population-based study
Variable | Odds ratio (for the univariate model)a | 95% CI | p-value | Odds ratio (for the adjusted model) | 95% CI | p-value |
---|---|---|---|---|---|---|
Sex (male vs the (reference = female)) | 1.53 | (1.51–1.56) | < .001 | 1.55 | (1.51–1.6) | < .001 |
Age group | ||||||
18–29 years | ref | |||||
30–39 years | 1.99 | (1.86–2.13) | < .001 | 2.01 | (1.78–2.26) | < .001 |
40–49 years | 4.91 | (4.61–5.24) | < .001 | 4.62 | (4.14–5.162) | < .001 |
50–59 years | 15.16 | (14.25–16.12) | < .001 | 13.63 | (12.24–15.173) | < .001 |
60–69 years | 44.69 | (42.05–47.49) | < .001 | 37.58 | (33.78–41.815) | < .001 |
70–79 years | 107.72 | (101.23–114.63) | < .001 | 92.75 | (83.26–103.311) | < .001 |
80–89 years | 183.23 | (171.09–196.22) | < .001 | 167.87 | (149.66–188.301) | < .001 |
More than or equal 90 years | 231.24 | (207.1–258.20) | < .001 | 237.82 | (200.19–282.524) | < .001 |
Region | ||||||
Albaha vs other regions | 0.97 | (0.91–1.03) | 0.328 | NA** | NA | NA |
Aljouf vs other regions | 0.62 | (0.51–0.76) | < .001 | 0.85 | (0.6–1.192) | 0.342 |
Almadina vs other regions | 0.93 | (0.89–0.96) | < .001 | 0.87 | (0.77–0.98) | 0.022 |
Alqasim vs other regions | 0.69 | (0.66–0.73) | < .001 | 0.73 | (0.64–0.826) | < .001 |
Asir vs other regions | 0.91 | (0.88–0.94) | < .001 | 0.9 | (0.8–1.007) | 0.065 |
Eastern Region vs other regions | 0.88 | (0.85–0.92) | < .001 | 0.93 | (0.83–1.048) | 0.234 |
Hail vs other regions | 0.86 | (0.81–0.9) | < .001 | 0.81 | (0.71–0.928) | 0.002 |
Jazan vs other regions | 0.95 | (0.91–0.99) | 0.039 | 1.34 | (1.18–1.528) | < .001 |
Makkah vs other regions | 1.67 | (1.64–1.70) | < .001 | 1.4 | (1.26–1.551) | < .001 |
Najran vs other regions | 0.47 | (0.43–0.52) | < .001 | 0.47 | (0.39–0.573) | < .001 |
Northern Boarders vs other regions | 0.73 | (0.46–1.17) | 0.187 | 0.32 | (0.07–3.220) | 0.370 |
Riyadh vs other regions | 0.66 | (0.65–0.68) | < 0.001 | 0.9 | (0.81–1.004) | 0.058 |
Tabouk vs other regions | 0.8 | (0.74–0.86) | < 0.001 | 1.18 | (0.99–1.412) | 0.068 |
Year of the visit | ||||||
2015 | Ref | |||||
2016 | 1.02 | (0.98–1.066) | 0.237 | 0.96 | (0.9–1.019) | 0.174 |
2017 | 1.19 | (1.14–1.23) | < 0.001 | 1.03 | (0.97–1.093) | 0.375 |
2018 | 1.08 | (1.04–1.12) | < 0.001 | 0.99 | (0.94–1.064) | 0.955 |
2019 | 1.12 | (1.08–1.16) | < 0.001 | 0.98 | (0.92–1.038) | 0.452 |
2020 | 1.10 | (1.06–1.14) | < 0.001 | 1.03 | (0.97–1.095) | 0.306 |
2021 | 1.09 | (1.05–1.13) | < 0.001 | 0.99 | (0.94–1.067) | 0.928 |
2022 | 1.02 | (0.98–1.06) | 0.237 | 0.96 | (0.9–1.018) | 0.161 |
Lab measurements | ||||||
Body mass index (BMI) (Kg/m2) | 0.99 | (0.98–1.10) | 0.073 | 1.03 | (1.02–1.028) | < .001 |
LDL-C (mg/dL) | 0.98 | (0.97–0.99) | < .001 | 1 | (1–0.999) | < .001 |
Triglyceride (mg/dL) | 1.03 | (1.01–1.04) | < .001 | 1.13 | (1.12–1.143) | < .001 |
HbA1c (%) | 1.43 | (1.43–1.44) | < .001 | 1.01 | (1–1.005) | < .001 |
Systolic Blood pressure (mmHg) | 1.02 | (1.01–1.03) | < .001 | 1.03 | (1.02–1.028) | < .001 |